医学
病态的
淋巴血管侵犯
新辅助治疗
危险系数
内科学
胃肠病学
化疗
病理分期
肿瘤科
比例危险模型
外科
癌症
转移
置信区间
乳腺癌
作者
Takaomi Hagi,Tomoki Makino,Makoto Yamasaki,Kotaro Yamashita,Koji Tanaka,Takuro Saito,Tsuyoshi Takahashi,Yukinori Kurokawa,Masaaki Motoori,Yutaka Kimura,Kiyokazu Nakajima,Eiichi Morii,Hidetoshi Eguchi,Yuichiro� Doki
出处
期刊:Annals of Surgery
[Lippincott Williams & Wilkins]
日期:2020-07-14
卷期号:275 (6): 1121-1129
被引量:32
标识
DOI:10.1097/sla.0000000000004238
摘要
Objective: To evaluate pathological response to NAC in metastatic LNs, and assess its clinical prognostic significance in patients with EC. Summary of Background Data: The pathological response to preoperative treatment is commonly evaluated in the PT. However, LN metastases strongly correlate with systemic micro-metastases. Thus, pathological evaluation of LN response could more accurately predict prognosis in EC patients undergoing NAC before surgery. Methods: We enrolled 371 consecutive patients who underwent triplet NAC followed by surgery for EC between January 2010 and December 2016. Pathological LN regression grade was defined by the proportion of viable tumor area within the whole tumor bed area for all metastatic LNs: grade I, >50%; II, 10%–50%; III, <10%; and IV, 0%. We analyzed the correlation of grade with clinico-pathological parameters. Results: Among 319 patients with clinically positive LNs, pathological LN regression grades were I/II/III/IV in 115/51/58/95 patients, and 191 patients (59.9%) showed discordance between the PT and LN pathological regression grades. LN regression grade significantly correlated with cN positive number, ypTNM, lymphovascular invasion, and clinical/pathological PT response. Multivariate analysis for recurrence-free survival revealed that LN regression grade [hazard ratio (HR) = 2.25, P < 0.001], ypT (HR = 1.65, P = 0.005), and ypT (HR = 1.62, P = 0.004) were independent prognostic factors, but not pathological PT regression grade (P = 0.67). Conclusions: Compared to PT response, pathological LN response better predicted long-term survival in EC patients who received NAC plus curative surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI